Your search for bevacizumab returned 9 results

Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.

There was no improvement in overall survival with bevacizumab.

Researchers say they have identified an unintended effect of Medicare’s 340B Drug Pricing Program; increases in spending for outpatient cancer treatments among patients with commercial insurance.

Researchers looked at the use of 6 biosimilars across 38 oncology practices and found that biosimilar use increased from 2019 to 2021.

High drug prices and ongoing shortages may prompt cancer patients to buy treatments online and fall prey to illegitimate pharmacies.

The approval was based on data from the phase 3 KEYNOTE-826 trial.

The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.

Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.

Study shows reductions in intraocular pressures and antiglaucoma medication use.